Poster Authors:

Yuhui Wang, Chuyue Yu, Qianqian Li1 Mingshuo Zhang, Junwen Zhang, Jiawen Xu, Xuan Liu, Xiaolan Huang, Qiang Gao, Pengwei Pan, Fang He

Pharmaron (Beijing) Co., Ltd, Beijing, China

This poster was presented at AACR 2025.

We present a case study showcasing the testing of antibody-drug conjugates (ADC) for efficacy and safety on organoids derived from patient-derived xenograft (PDX) models and organoids derived from healthy intestinal tissue.

This study highlights the platform’s capabilities demonstrated through ADCs that target HER2.

• Over 150 PDX organoids from diverse cancer types and normal organoids from intestinal tissue were developed.
• HER2 expression was assessed via multi-omics platforms RNAseq, WES, Western blot, and IHC staining.
• Organoid viability testing was performed on 14 organoids with varying HER2 levels using four ADCs and their payload and payload+linker controls.
• Safety evaluation was conducted using intestinal organoids.

Key findings from ADC Testing on PDX organoids and Intestinal organoids:

• Efficacy: High HER2 expression correlated with increased sensitivity to ADC treatment, while lower expression indicated resistance. Payloads alone caused broad cytotoxicity.
• Safety: Intestinal organoids showed minimal response to ADCs, revealing a favorable therapeutic window with reduced gastrointestinal side effects.

Download the full poster to learn more about our ADC testing options in organoids.